Literature DB >> 9158118

Venous allografts for infrainguinal vascular bypass.

E Rebane1, H Tikko, E Tunder, U Lepner, A Helberg, A Pulges, T Vaasna, S Suba, J Lieberg, V Tamm, T Ellervee, O Vasar.   

Abstract

Between 1978 and 1993, 107 patients received venous allografts for infrainguinal revascularization because autogenous material was unavailable. These operations comprised 7.4% of 1442 reversed vein bypass procedures performed during the same period. Alloveins were harvested during varicose vein stripping and stored up to 10 days in saline solution containing heparin and antibiotics. Veins with or without minimal degenerative changes were used and when necessary segments were sutured end-to-end to obtain a convenient length. The patients comprised 95 men and 12 women of age range 44-87 years. All operations were performed for limb salvage (rest pain and gangrene); 40 femoropopliteal and 67 femorocrural bypasses were performed; 66 were primary reconstructions and 41 secondary reconstructions. The operative mortality rate was 3.7%. Early thrombosis occurred in 18 patients (16.8%), nine of whom were successfully reoperated upon. The cumulative patency rates for all bypass operations was 82.9%, 38.7% and 21.3% at 30 days, 3 and 5 years, respectively, the limb salvage rates being 84.8%, 48.0% and 29.2%, respectively. Allografts may have a place in lower-limb bypass surgery in the absence of veins, polytetrafluoroethylene or human umbilical vein.

Entities:  

Mesh:

Year:  1997        PMID: 9158118     DOI: 10.1016/s0967-2109(96)00080-4

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  2 in total

Review 1.  Basic data related to surgical infrainguinal revascularization procedures: a twenty year update.

Authors:  Kenneth R Ziegler; Akihito Muto; Sammy D D Eghbalieh; Alan Dardik
Journal:  Ann Vasc Surg       Date:  2011-04       Impact factor: 1.466

2.  [Homologous vein transplantation in cruropedal arterial reconstruction].

Authors:  B Luther; K M Balzer; P Reinecke; R Wassmuth; W Sandmann
Journal:  Chirurg       Date:  2004-02       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.